The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Report Overview

Table of Contents

2214.76

Select License Type

£2,214.77	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£4,429.53	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£6,644.30	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,214.77	Add to Wishlist
Change Currency	GBP EURO USD

Market	Healthcare and Medical
Report Type	Market Research
Country	Global
Published	15 December 2009
Number of Pages	250
Report Delivery	Email
Delivery Lead Time	-
Publisher	GBI Research

Summary

The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis provides in-depth analysis of unmet needs, drivers and barriers that impact the global metabolic disorder therapeutics market. The report analyzes the markets for metabolic disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:

• Annualized market data for the metabolic disorder therapeutics market from 2000 to 2008, forecast forward to 2015
• Analysis of the leading therapeutic segments including diabetes and obesity.
• Analysis of the metabolic disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
• Market characterization of the metabolic disorder therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
• Key drivers and barriers that have a significant impact on the market
• Coverage of pipeline molecules in various phases of drug development
• Competitive benchmarking of leading companies. The key companies studied in this report are Novo Nordisk A/S, Eli Lilly, Takeda Pharmaceuticals, Sanofi-aventis and GlaxoSmithKline.
• Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global metabolic disorder therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

• Align product portfolio to the markets with high growth potential
• Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
• Develop key strategic initiatives by understanding key focus areas of leading companies
• Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£2,214.77	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£4,429.53	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£6,644.30	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,214.77	Add to Wishlist
Change Currency	GBP EURO USD

1 Table of Contents
1 Executive Summary
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
4 Global Metabolic Disorder Therapeutics Market: Market Overview
4.1 Introduction
4.2 Revenue Forecasts for the Global Metabolic Disorder Therapeutics Market
4.2.1 Sales Value
4.2.2 Sales Volume
4.2.3 Annual Cost of Therapy
4.2.4 Treatment Usage Patterns
4.2.5 Geographical Segmentation
4.2.6 Generics’ Share in the Global Metabolic Disorders Market
4.3 SWOT Analysis
4.3.1 Strength
4.3.2 Weakness
4.3.3 Opportunity
4.3.4 Threat
4.4 Metabolic Disorder Therapeutics Market Drivers
4.4.1 Steady Growth in the Ageing Population
4.4.2 Improvements in the Diagnosis of the Disease
4.4.3 Launch of New Treatments with More Innovative Medicines in Pipeline
4.4.4 Increase in the Incidence of Lifestyle Diseases such as Obesity and Diabetes
4.5 Metabolic Disorder Therapeutics Market Restraints
4.5.1 Patent Expirations
4.5.2 Concerns over Drug Safety
4.5.3 Tightened Reimbursement pressures causing problems in the global Metabolic Disorder Therapeutics market growth
5 Global Metabolic Disorder Therapeutics Market: Geographical Distribution of Revenues
5.1 Geographic Break-up
5.2 The US
5.2.1 Sales Value
5.2.2 Sales Volume
5.2.3 Annual Cost of Therapy
5.2.4 Treatment Usage Patterns
5.3 Top Five Countries in Europe
5.3.1 Sales Value
5.3.2 Sales Volume
5.3.3 Annual Cost of Therapy
5.3.4 Treatment Usage Patterns
5.4 Japan
5.4.1 Sales Value
5.4.2 Sales Volume
5.4.3 Annual Cost of Therapy
5.4.4 Treatment Usage Patterns
6 Global Metabolic Disorder Therapeutics Market: Therapeutic Distribution of Revenues
6.1 Diabetes Market
6.1.1 Introduction
6.1.2 Unmet Needs
6.1.3 Sales Value
6.1.4 Sales Volume
6.1.5 Annual Cost of Therapy
6.1.6 Treatment Usage Patterns
6.1.7 Geographical Segmentation
6.1.8 Generics’ Share in the Global Diabetes Market
6.1.9 Drivers
6.1.10 Inhibitors
6.2 Obesity Market
6.2.1 Introduction
6.2.2 Sales Value
6.2.3 Sales Volume
6.2.4 Annual Cost of Therapy
6.2.5 Treatment Usage Patterns
6.2.6 Geographical Segmentation
6.2.7 Generics’ Share in the Global Obesity Market
6.2.8 Drivers of Obesity Market
6.2.9 Restraints of Obesity Market
7 Global Metabolic Disorder Therapeutics Market: Pipeline Analysis
7.1 Introduction
7.1.1 Obesity
7.1.2 R&D Strategies
7.2 R&D Trends
7.2.1 New Promising Treatments for Diabetic Retinopathy
7.2.2 Identifying Biomarkers
7.2.3 Combination Drugs
7.2.4 First-in-class Insulin Pills (oral delivery) in Development
7.3 New Drug Insulin Delivery Systems
7.3.1 Altea Therapeutics Transdermal Passport™ System
7.3.2 Technosphere®/Insulin Mimics Early Post-Prandial Insulin Release
7.4 Profiles of Key Novel Late-Stage Drugs
7.5 Major Marketed Drugs under Late-Stage Pipeline
7.5.1 Eisai’s Actos
7.5.2 Amgen’s Aranesp
7.5.3 Eli Lilly’s Byetta
8 Global Metabolic Disorders Therapeutics Market: Competitive Landscape
8.1 Diabetes Market Overview
8.2 Market Share Analysis: Diabetes Therapeutics
8.3 Obesity Market Overview
8.4 Market Share Analysis: Obesity Therapeutics
8.5 Competitive Profiling
8.5.1 Novo Nordisk
8.5.2 Sanofi-aventis
8.5.3 Takeda
8.5.4 Eli Lilly
8.5.5 GlaxoSmithKline (GSK)
8.5.6 Merck & Co Inc.
8.5.7 Amylin Pharmaceuticals
8.5.8 Roche
8.5.9 Abbott
9 Global Metabolic Disorders Therapeutics Market: M&A Landscape
9.1 Overview
9.1.1 Ligand Pharmaceuticals acquired Metabasis Therapeutics in October 2009
9.1.2 CombinatoRx, Inc. Acquired Neuromed Pharmaceuticals, Inc. in August 2009
9.1.3 Mylan Laboratories Acquired Matrix Laboratories Limited in March 2009
9.1.4 Pfizer Acquired Wyeth in January 2009
9.1.5 Wyeth Acquired Thiakis Ltd. in December 2008
9.1.6 Bellus Health Inc. Acquired Innodia Inc in July 2008
9.1.7 GlaxoSmithKline Acquired Sirtris Pharmaceuticals in April 2008
9.1.8 Point Therapeutics and Dara Biosciences Merged in February 2008
9.1.9 Teva Pharmaceutical Industries Acquired Cogenesys, Inc. in January 2008
9.2 R&D Licensing Agreements
9.2.1 Deals by Indication
9.2.2 Deals by Phase
9.2.3 Deals by Geography
9.2.4 Deals by Licensing Type
9.2.5 Deals by Value ($)
9.2.6 Preclinical
9.2.7 Phase I
9.2.8 Phase II
9.2.9 Phase III
9.2.10 Approved
10 Appendix
10.1 Market Definitions
10.2 Key Support Data
10.3 Abbreviations
10.4 Research Methodology
10.4.1 Epidemiology-based Forecasting
10.5 Related Reports
10.6 Contact Us
10.7 Disclaimer
10.8 Sources
1.1 List of Tables
Table 1: Metabolic Disorders Market, Global, Sales Value ($ bn), 2000-2008
Table 2: Metabolic Disorders Market, Global, Sales Value ($ bn), 2008-2015
Table 3: Metabolic Disorders Market, Global, Sales Volume (bn), 2000-2008
Table 4: Metabolic Disorders Market, Global, Sales Volume (bn), 2008-2015
Table 5: Metabolic Disorders Market, Global, Annual Cost of Therapy ($), 2000-2008
Table 6: Metabolic Disorders Market, Global, Annual Cost of Therapy ($), 2008-2015
Table 7: Metabolic Disorders Market, Global, Treatment Usage Patterns, 2000-2008
Table 8: Metabolic Disorders Market, Global, Treatment Usage Patterns, 2008-2015
Table 9: Metabolic Disorders Market, Global, Sales of Generics Vs Branded Drugs ($ bn), 2000-2008
Table 10: Metabolic Disorders Market, Global, Sales of Generics Vs Branded Drugs ($ bn), 2008-2015
Table 11: Metabolic Disorders Market, US, Sales Value ($ bn), 2000-2008
Table 12: Metabolic Disorders Market, US, Sales Value ($ bn), 2008-2015
Table 13: Metabolic Disorders Market, US, Sales Volume (bn), 2000-2008
Table 14: Metabolic Disorders Market, US, Sales Volume (bn), 2008-2015
Table 15: Metabolic Disorders Market, US, Annual Cost of Therapy ($), 2000-2008
Table 16: Metabolic Disorders Market, US, Annual Cost of Therapy ($), 2008-2015
Table 17: Metabolic Disorders Market, US, Treatment Usage Patterns, 2000-2008
Table 18: Metabolic Disorders Market, US, Treatment Usage Patterns, 2008-2015
Table 19: Metabolic Disorders Market, Top Five Countries in Europe, Sales Value ($ bn), 2000-2008
Table 20: Metabolic Disorders Market, Top Five Countries in Europe, Sales Value ($ bn), 2008-2015
Table 21: Metabolic Disorders Market, Top Five Countries in Europe, Sales Volume (bn), 2000-2008
Table 22: Metabolic Disorders Market, Top Five Countries in Europe, Sales Volume (bn), 2008-2015
Table 23: Metabolic Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2000-2008
Table 24: Metabolic Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2008-2015
Table 25: Metabolic Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns, 2000-2008
Table 26: Metabolic Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns, 2008-2015
Table 27: Metabolic Disorders Market, Japan, Sales Value ($ bn), 2000-2008
Table 28: Metabolic Disorders Market, Japan, Sales Value ($ bn), 2008-2015
Table 29: Metabolic Disorders Market, Japan, Sales Value ($ bn), 2000-2008
Table 30: Metabolic Disorders Market, Japan, Sales Value ($ bn), 2008-2015
Table 31: Metabolic Disorders Market, Japan, Annual Cost of Therapy ($), 2000-2008
Table 32: Metabolic Disorders Market, Japan, Annual Cost of Therapy ($), 2008-2015
Table 33: Metabolic Disorders Market, Japan, Treatment Usage Patterns, 2000-2008
Table 34: Metabolic Disorders Market, Japan, Treatment Usage Patterns, 2008-2015
Table 35: Metabolic Disorders Market, Global, Diabetes Sales Value ($ bn), 2000-2008
Table 36: Metabolic Disorders Market, Global, Diabetes Sales Value ($ bn), 2008-2015
Table 37: Metabolic Disorders, Global, Diabetes Sales Volume (billion), 2000-2008
Table 38: Metabolic Disorders, Global, Diabetes Sales Volume (billion), 2008-2015
Table 39: Metabolic Disorders Market, Global, Diabetes Annual Cost of Therapy ($), 2000-2008
Table 40: Metabolic Disorders Market, Global, Diabetes Annual Cost of Therapy ($), 2008-2015
Table 41: Metabolic Disorders, Global, Diabetes Treatment Usage Patterns, 2000-2008
Table 42: Metabolic Disorders, Global, Diabetes Treatment Usage Patterns, 2008-2015
Table 43: Metabolic Disorders Market, Global, Diabetes Market Geographical Segmentation, 2000-2008
Table 44: Metabolic Disorders Market, Global, Diabetes Market Geographical Segmentation, 2008-2015
Table 45: Metabolic Disorders Market, Global, Diabetes Branded Vs Generics, 2000-2008
Table 46: Metabolic Disorders Market, Global, Diabetes Branded Vs Generics, 2008-2015
Table 47: Metabolic Disorders Market, Global, Obesity Diseases Population, 2000-2008
Table 48: Metabolic Disorders Market, Global, Obesity Diseases Population, 2008-2015
Table 49: Metabolic Disorders Market, Global, Obesity Market Sales Volume (billion), 2000-2008
Table 50: Metabolic Disorders Market, Global, Obesity Market Sales Volume (billion), 2008-2015
Table 51: Metabolic Disorders Market, Global, Annual Cost of Obesity Treatment, 2000-2008
Table 52: Metabolic Disorders Market, Global, Annual Cost of Obesity Treatment, 2008-2015
Table 53: Metabolic Disorders Market, Global, Obesity Treatment Usage Patterns, 2000-2008
Table 54: Metabolic Disorders Market, Global, Obesity Treatment Usage Patterns, 2008-2015
Table 55: Metabolic Disorders Market, Global, Obesity Market Geographical Segmentation, 2000-2008
Table 56: Metabolic Disorders Market, Global, Obesity Market Geographical Segmentation, 2008-2015
Table 57: Metabolic Disorders Market, Global, Obesity Market, Generics Vs Branded Drugs, 2000-2008
Table 58: Metabolic Disorders Market, Global, Obesity Market, Generics Vs Branded Drugs, 2008-2015
Table 59: Metabolic Disorders Therapeutics Market, Novo Nordisk, Pipeline Products, December 2009
Table 60: Metabolic Disorders Therapeutics Market, Sanofi-Aventis, Pipeline Products, December 2009
Table 61: Metabolic Disorders Therapeutics Market, Takeda, Pipeline Products, December 2009
Table 62: Metabolic Disorders Therapeutics Market, Eli Lilly, Pipeline Products, December 2009
Table 63: Metabolic Disorders Therapeutics Market, GSK, Pipeline Products, December 2009
Table 64: Metabolic Disorders Therapeutics Market, Merck, Pipeline Products, December 2009
Table 65: Metabolic Disorders Therapeutics Market, Amylin, Pipeline Products, December 2009
Table 66: Metabolic Disorders Therapeutics Market, Roche, Pipeline Products, December 2009
Table 67: Metabolic Disorders Therapeutics Market, Global, Major M&A Deals, 2008-2009
Table 68: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008-2009
Table 69: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I, 2008-2009
Table 70: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008-2009
Table 71: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III, 2008-2009
Table 72: Metabolic Disorders Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008-2009
1.1 List of Figures
Figure 1: Metabolic Disorders Market, Global, Market Drivers and Restraints, 2008
Figure 2: Metabolic Disorders Market, Global, Sales Value ($ bn), 2000-2015
Figure 3: Metabolic Disorders Market, Global, Sales Volume (bn), 2000-2015
Figure 4: Metabolic Disorders Market, Global, Annual Cost of Therapy ($), 2000-2015
Figure 5: Metabolic Disorders Market, Global, Treatment Usage Patterns, 2000-2015
Figure 6: Metabolic Disorders Market, Global, Diseased Population (million), 2000-2015
Figure 7: Metabolic Disorders Market, Global, Treatment Seeking Population (million), 2000-2015
Figure 8: Metabolic Disorders Market, Global, Diagnosed Population (million), 2000-2015
Figure 9: Metabolic Disorders Market, Global, Prescription Population (million), 2000-2015
Figure 10: Metabolic Disorders Market, Global, Sales of Generics Vs Branded Drugs ($ bn), 2000-2015
Figure 11: Metabolic Disorders Market, Global, SWOT Analysis, 2008
Figure 12: Metabolic Disorders Market, Global, Drivers and Restraints, 2008
Figure 13: Metabolic Disorders Market, US, Sales Value ($ bn), 2000-2015
Figure 14: Metabolic Disorders Market, US, Sales Volume (bn), 2000-2015
Figure 15: Metabolic Disorders Market, US, Annual Cost of Therapy ($), 2000-2015
Figure 16: Metabolic Disorders Market, US, Treatment Usage Patterns, 2000-2015
Figure 17: Metabolic Disorders Market, US, Diseased Population, 2000-2015
Figure 18: Metabolic Disorders Market, US, Treatment Seeking Population, 2000-2015
Figure 19: Metabolic Disorders Market, US, Diagnosed Population, 2000-2015
Figure 20: Metabolic Disorders Market, US, Prescription Population, 2000-2015
Figure 21: Metabolic Disorders Market, Top Five Countries in Europe, Sales Value ($ bn), 2000-2015
Figure 22: Metabolic Disorders Market, Top Five Countries in Europe, Sales Volume (bn), 2000-2015
Figure 23: Metabolic Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2000-2015
Figure 24: Metabolic Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns, 2000-2015
Figure 25: Metabolic Disorders Market, Top Five Countries in Europe, Diseased Population, 2000-2015
Figure 26: Metabolic Disorders Market, Top Five Countries in Europe, Treatment Seeking Population, 2000-2015
Figure 27: Metabolic Disorders Market, Top Five Countries in Europe, Diagnosed Population, 2000-2015
Figure 28: Metabolic Disorders Market, Top Five Countries in Europe, Prescription Population, 2000-2015
Figure 29: Metabolic Disorders Market, Japan, Sales Value ($ bn), 2000-2015
Figure 30: Metabolic Disorders Market, Japan, Sales Volume ($ bn), 2000-2015
Figure 31: Metabolic Disorders Market, Japan, Annual Cost of Therapy ($), 2000-2015
Figure 32: Metabolic Disorders Market, Japan, Treatment Usage Patterns, 2000-2015
Figure 33: Metabolic Disorders Market, Japan, Diseased Population, 2000-2015
Figure 34: Metabolic Disorders Market, Japan, Treatment Seeking Population, 2000-2015
Figure 35: Metabolic Disorders Market, Japan, Diagnosed Population, 2000-2015
Figure 36: Metabolic Disorders Market, Japan, Prescription Population, 2000-2015
Figure 37: Metabolic Disorders Market, Global, Diabetes Sales Value ($ bn), 2000-2015
Figure 38: Metabolic Disorders, Global, Diabetes Sales Volume (billion), 2000-2015
Figure 39: Metabolic Disorders Market, Global, Diabetes Annual Cost of Therapy ($), 2000-2015
Figure 40: Metabolic Disorders, Global, Diabetes Treatment Usage Patterns, 2000-2015
Figure 41: Metabolic Disorders Market, Global, Diabetes Diseased Population, 2000-2015
Figure 42: Metabolic Disorders Market, Global, Diabetes Treatment Seeking Population, 2000-2015
Figure 43: Metabolic Disorders Market, Global, Diabetes Diagnosed Population, 2000-2015
Figure 44: Metabolic Disorders Market, Global, Diabetes Prescription Population, 2000-2015
Figure 45: Metabolic Disorders Market, Global, Diabetes Market Segmentation by Geography, 2008 and 2015
Figure 46: Metabolic Disorders Market, Global, Diabetes Market Geographical Segmentation, 2000-2015
Figure 47: Metabolic Disorders Market, Global, Diabetes Market, Geography Benchmarking, 2008
Figure 48: Metabolic Disorders Market, Global, Diabetes Branded Vs Generics, 2000-2015
Figure 49: Metabolic Disorders Market, Global, Diabetes Market, Generics Share, 2008 and 2015
Figure 50: Metabolic Disorders Market, Global, Diabetes Market Drivers and Restraints, 2008
Figure 51: Metabolic Disorders Market, Global, Obesity Diseases Population, 2000-2015
Figure 52: Metabolic Disorders Market, Global, Obesity Market Sales Volume (billion), 2000-2015
Figure 53: Metabolic Disorders Market, Global, Annual Cost of Obesity Treatment, 2000-2015
Figure 54: Metabolic Disorders Market, Global, Obesity Treatment Usage Patterns, 2000-2015
Figure 55: Metabolic Disorders Market, Global, Obesity Diseased Population, 2000-2015
Figure 56: Metabolic Disorders Market, Global, Obesity Treatment Seeking Population, 2000-2015
Figure 57: Metabolic Disorders Market, Global, Obesity Diagnosed Population, 2000-2015
Figure 58: Metabolic Disorders Market, Global, Obesity Prescription Population, 2000-2015
Figure 59: Metabolic Disorders Market, Global, Obesity Market Geographical Segmentation, 2000-2015
Figure 60: Metabolic Disorders Market, Global, Obesity Market Distribution by Geography, 2008 and 2015
Figure 61: Metabolic Disorders Market, Global, Obesity Market, Geography Benchmarking, 2008 and 2015
Figure 62: Metabolic Disorders Market, Global, Obesity Market, Generics Vs Branded Drugs, 2000-2015
Figure 63: Metabolic Disorders Market, Global, Obesity Market, Generics Vs Branded Drugs Market Share, 2008 and 2015
Figure 64: Metabolic Disorders Market, Global, Obesity Market Drivers and Restraints, 2009
Figure 65: Diabetes Therapeutics Market, Global, Revenue of Top Six Players, 2006-2008
Figure 66: Metabolic Disorder Market, Global, Competitive Analysis of Top Three Manufacturers in the Diabetes Market, 2006-2008
Figure 67: Diabetes Therapeutics Market, Global, Market Share of Top Manufacturers, 2008
Figure 68: Obesity Therapeutics Market, Global, Revenue of Top Six Players, 2006-2008
Figure 69: Metabolic Disorder Market, Global, Competitive Analysis of Top Three Manufacturers in the Obesity Market, 2006-2008
Figure 70: Obesity Therapeutics Market, Global, Market Share of Top Manufacturers, 2008
Figure 71: Diabetes Therapeutics Market, Global, Competitive Landscape, 2008
Figure 72: Metabolic Disorders Therapeutics Market, Global, Novo Nordisk, Revenue Segmentation, 2008
Figure 73: Metabolic Disorders Therapeutics Market, Novo Nordisk, Diabetes Revenue by Product, 2008
Figure 74: Metabolic Disorders Therapeutics Market, Sanofi-Aventis, Revenue Segmentation, 2008
Figure 75: Metabolic Disorders Therapeutics Market, Sanofi-aventis, Diabetes Revenue by Product, 2008
Figure 76: Metabolic Disorders Therapeutics Market, Takeda, Diabetes Revenue as Percentage of Total Revenue, 2008
Figure 77: Metabolic Disorders Therapeutics Market, Eli Lilly, Diabetes Revenue as Percentage of Total Revenue, 2008
Figure 78: Metabolic Disorders Therapeutics Market, Eli Lilly, Diabetes Revenue by Product, 2008
Figure 79: Metabolic Disorders Therapeutics Market, GlaxoSmithKline, Revenue Segmentation, 2008
Figure 80: Metabolic Disorders Therapeutics Market, GSK, Diabetes Revenue by Product, 2008
Figure 81: Metabolic Disorders Therapeutics Market, Merck, Revenue Segmentation, 2008
Figure 82: Metabolic Disorders Therapeutics Market, Amylin, Revenue Segmentation, 2008
Figure 83: Metabolic Disorders Therapeutics Market, GSK, Diabetes Revenue by Product, 2008
Figure 84: Metabolic Disorders Therapeutics Market, Roche, Revenue Segmentation, 2008
Figure 85: Metabolic Disorders Therapeutics Market, Abbott, Revenue Segmentation, 2008
Figure 86: Metabolic Disorders Therapeutics Market, Global, M&A Deals by Indication, 2008-2009
Figure 87: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Indication, 2008-2009
Figure 88: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Phase, 2008-2009
Figure 89: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Geography, 2008-2009
Figure 90: Metabolic Disorders Therapeutics Market, Global, Major Agreements By Type, 2008-2009
Figure 91: Metabolic Disorders Therapeutics Market, Global, Major Licensing Agreements By Value, 2008-2009

Change Currency

GBP

EURO

USD

Last Viewed

The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

AES Ocean LNG Terminal - Analysis and Forecasts of Terminal wise Capacity and Associated Contracts, Construction and Trade Information

UK Foodservice Industry Outlook to 2010: Supplier and Caterer Marketing and Sales Strategies and the Impact of Recession and Recovery

Zhejiang LNG Terminal - Analysis and Forecasts of Terminal wise Capacity and Associated Contracts, Construction and Trade Information

Sakhalin LNG Terminal - Analysis and Forecasts of Terminal wise Capacity and Associated Contracts, Construction and Trade Information

Healthcare and Medical Company Profiles

Healthcare and Medical Company Profiles contain up to date financial, strategic, operational, SWOT analysis and product information on the activities of thousands of healthcare and medical companies.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website. If a sale is made from your visitor, you earn commission (a fixed percentage of the price of a product).

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Select License Type

Speak to an Advisor

Select License Type

Table of Contents

Change Currency

Last Viewed

Healthcare and Medical Company Profiles

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel